Archives
-
γH2AX as a Translational Readout for FLASH-RT
2026-08-15
A mechanistic and strategic guide to using γ-H2AX immunofluorescence to connect radiosensitization, DNA double-strand break detection, and translational decision-making in FLASH-RT research.
-
CKI 7 Dihydrochloride: From CK1 to Translation
2026-08-14
A translational research perspective on using CKI 7 dihydrochloride to interrogate Casein kinase 1 biology, connect pathway-level findings to NSCLC metastasis research, and design stronger mechanistic validation workflows.
-
IWP-2: Designing Better Wnt Inhibition Assays
2026-08-14
IWP-2 is a Wnt production inhibitor that enables mechanistic interrogation of ligand-dependent signaling in cancer research. This article connects its PORCN biology and MKN28-cell evidence with a morphology-first assay strategy inspired by modern cardiomyocyte profiling.
-
LGK-974 (Porcupine Inhibitor): Assay Guide
2026-08-13
This scenario-driven guide explains how LGK-974 (Porcupine Inhibitor), SKU B2307, can improve the design and interpretation of Wnt-pathway cell assays. It covers solvent handling, dose selection, target-engagement controls, viability interpretation, and practical product-selection criteria.
-
Diethylmaleate: Designing Better Redox Assays
2026-08-13
Diethylmaleate is a versatile redox perturbation tool for connecting glutathione depletion with ROS, GST activity, apoptosis, and resistance phenotypes. This guide focuses on assay architecture, controls, and interpretation rather than simply describing oxidative stress applications.
-
Fenipentol Workflows for GI Physiology Research
2026-08-12
Fenipentol, also called 1-Phenyl-1-pentanol, is a practical probe for choleretic, hepatobiliary, and estrogen receptor-related experiments. This workflow-focused guide explains how to control identity, solvent exposure, secretion readouts, and isomer-specific interpretation while adapting insights from recent anti-fibrotic research.
-
IWP-L6: Mapping Wnt-to-Metabolism Causality
2026-08-12
IWP-L6 is a potent Porcupine inhibitor for dissecting how Wnt ligand biogenesis influences signaling, metabolism, and tissue development. This article presents an assay-centered framework that separates upstream Porcn inhibition from downstream Wnt responses and interprets metabolic phenotypes more rigorously.
-
Reserpine (N1867): Practical Lab Workflow Guide
2026-08-11
Reserpine (SKU N1867) provides a defined research reagent for controlled neurotransmitter depletion, antihypertensive mechanism studies, and neuropharmacology workflows. Its water and ethanol insolubility, DMSO-dependent preparation, storage requirements, and potent biological activity make it unsuitable for clinical, diagnostic, or therapeutic use.
-
LGK-974: A Precision PORCN Inhibitor
2026-08-11
LGK-974 is a potent PORCN inhibitor that blocks Wnt ligand secretion and suppresses canonical Wnt pathway readouts. Preclinical evidence supports its use for Wnt pathway assays, pancreatic cancer RNF43 mutation models, and investigation of excessive bone formation in Sost-deficient mice.
-
Hydroxychloroquine Sulfate: Workflow Guide
2026-08-10
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible research reagent for examining autophagy pathway modulation and TLR7/9-associated immune signaling. It is suited to controlled cell and animal research workflows, but not to protocols requiring DMSO or ethanol solubility, long-term solution storage, or direct clinical interpretation.
-
Salinomycin A3785 for Reliable Cell Assays
2026-08-09
This scenario-driven guide explains how Salinomycin (SKU A3785) can be incorporated into cell viability, proliferation, cytotoxicity, and mechanism-focused experiments. It covers solvent compatibility, storage, protocol design, interpretation of apoptosis-related readouts, and practical criteria for selecting a dependable research reagent.
-
CKI 7 dihydrochloride: CK1 Workflow Guide
2026-08-08
Build reproducible CK1 perturbation experiments with CKI 7 dihydrochloride across Wnt, circadian, phosphorylation, and cancer-cell assays. The workflow emphasizes dose finding, orthogonal controls, and careful separation of CK1 biology from the MAPK10–KRT16 metastasis mechanism reported in recent NSCLC research.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-08-07
Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 can overcome the paradoxical increase in invasion and epithelial-to-mesenchymal transition caused by CDK4/6 inhibition alone. The study links this synergy to GSK3β-mediated Wnt/β-catenin activation and disrupted Wnt/β-catenin–TGF-β/Smad crosstalk, providing a mechanistic basis for combination treatment in pancreatic ductal adenocarcinoma.
-
Murine RNase Inhibitor: Oxidation-Resistant RNA Protection
2026-08-07
Murine RNase Inhibitor delivers oxidation-resistant inhibition of pancreatic-type RNases, safeguarding RNA integrity in sensitive workflows. This recombinant protein, produced in E. coli, enables robust RNA degradation prevention in real-time RT-PCR and cDNA synthesis, even under low-reducing conditions. Its enhanced stability and specificity make it a gold standard for advanced molecular biology applications.
-
Nullscript: Redefining HDAC Inhibition in Translational Rese
2026-08-06
This thought-leadership article examines Nullscript, a next-generation histone deacetylase inhibitor (HDACi) from APExBIO, through the lens of translational research. It explores the mechanistic nuances distinguishing Nullscript from other HDAC inhibitors, reports on its validated in vivo efficacy in myocardial infarct size reduction, and provides strategic, protocol-level guidance for researchers in cardiac, neurodegenerative, and cancer models. The piece synthesizes published data, connects cross-domain insights, and critically assesses Nullscript’s potential to shape the future of epigenetic modulation.